KNSA Kiniksa Pharmaceuticals International plc

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Date	Price Target	Rating	Analyst
3/13/2025	$40.00	Buy	Citigroup
9/13/2024	$40.00	Buy	Jefferies
5/3/2024	$34.00	Overweight	Wells Fargo
12/29/2021	$37.00 → $34.00	Buy	B of A Securities

Kiniksa Pharmaceuticals International plc

Peers

Recent Analyst Ratings for Kiniksa Pharmaceuticals International plc

Kiniksa Pharmaceuticals International plc Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $489,244 worth of Class A Ordinary Share (17,300 units at $28.28), decreasing direct ownership by 15% to 61,563 units (SEC Form 4)

Director Quart Barry D exercised 27,448 units of Class A Ordinary Share at a strike of $3.80 and sold $833,001 worth of Class A Ordinary Share (27,448 units at $30.35) (SEC Form 4)

CHIEF OPERATING OFFICER Tessari Eben exercised 70,867 units of Class A Ordinary Share at a strike of $10.36 and sold $2,160,035 worth of Class A Ordinary Share (70,867 units at $30.48) (SEC Form 4)

Director Cole G Bradley converted options into 3,173 units of Class A Ordinary Share, increasing direct ownership by 34% to 12,546 units (SEC Form 4)

Director Baker Bros. Advisors Lp was granted 16,794 units of Class A Ordinary Shares (SEC Form 4)

Director Levy Richard S converted options into 3,173 units of Class A Ordinary Share, increasing direct ownership by 22% to 17,373 units (SEC Form 4)

Director Malley Thomas converted options into 3,173 units of Class A Ordinary Shares, increasing direct ownership by 34% to 12,546 units (SEC Form 4)

Director Mccain Tracey L converted options into 3,173 units of Class A Ordinary Share, increasing direct ownership by 34% to 12,546 units (SEC Form 4)

Director Popovits Kimberly J converted options into 3,173 units of Class A Ordinary Share, increasing direct ownership by 34% to 12,546 units (SEC Form 4)

Director Quart Barry D converted options into 3,173 units of Class A Ordinary Share, increasing direct ownership by 34% to 12,546 units (SEC Form 4)